Apoptosis

Apoptosis is an autonomous, genetically controlled, orderly death of cells to maintain the stability of the internal environment. Unlike necrosis, apoptosis is not a passive process, but an active one, involving the activation, expression and regulation of a series of genes, and it is not a phenomenon of autologous damage under pathological conditions, but an active death process for better adaptation to the survival environment. Apoptosis is a fundamental biological phenomenon of cells and plays a necessary role in the removal of unwanted or abnormal cells in multicellular organisms. It plays an important role in the evolution of organisms, the stability of the internal environment, and the development of several systems. Apoptosis is not only a specific type of cell death, but also has important biological significance and complex molecular biological mechanisms.

Cat. No.	Product name
BP10394	DMU-212
BP10394	DMU-212, a methylated form of Resveratrol, shows antimitotic, antiproliferative, and antioxidant activities. DMU-212 induces mitotic arrest through the activation of ERK1/2 protein and the promotion of apoptosis.
BP10177	Docetaxel
BP10177	Docetaxel is a microtubule inhibitor that inhibits microtubule disassembly (IC50: 0.2 μM).
BP10584	Docetaxel trihydrate
BP10584	Docetaxel is an antineoplastic agent that has a unique mechanism of action as an inhibitor of cellular mitosis and that currently plays a central role in the therapy of many solid tumor including breast and lung cancer. Therapy with docetaxel has been associated with a low rate of serum enzyme elevations and rarely to instances of acute hepatic necrosis generally due to severe hypersensitivity reactions or sepsis.
BP10209	Domatinostat tosylate
BP10209	4SC-202 is a selective inhibitor of class I HDAC for HDAC1/2/3 (IC50: 1.20/1.12/0.57 μM). It also displays inhibitory activity against Lysine-specific demethylase 1 (LSD1).
BP10611	Dp44mT
BP10611	Dp44mT, a effective iron chelator, has selective antitumor activity.
BP10434	D-Pantothenic acid hemicalcium salt
BP10434	D-Pantothenic acid hemicalcium salt, a kind of water soluble vitamin, can reduce the patulin content of the apple juice.
BP10515	DPN
BP10515	DPN is an selective agonist of estrogen receptor β (ERβ) .
BP10298	Dracorhodin perchlorate
BP10298	Dracorhodin perchlorate inhibits cell growth, and induces apoptosis in fibroblasts in a dose-and time-dependent manner, arresting cell cycle at G1 phase, may as a candidate for anti-breast cancer. Dracorhodin perchlorate can inhibit high glucose-induced serum and glucocorticoid induced protein kinase 1 (SGK1) and fibronectin(FN) expression in human mesangial cells, and this may be part of the mechanism of preventing and treating renal fibrosis of DN.
BP10811	DTP3
BP10811	DTP3 is a selective MKK7/GADD45β inhibitor, which inhibits cancer-selective NF-κB survival pathway.
BP10204	Duocarmycin A
BP10204	Duocarmycin A, an antitumor antibiotic, is a DNA alkylator and efficiently alkylates adenine N3 at the 3′ end of AT-rich sequences in the DNA. Duocarmycin A, as a chemotherapeutic agent, results in HLC-2 cells typically apoptotic changes.
BP10712	Dutasteride
BP10712	Dutasteride is a 5-alpha-reductase inhibitor that inhibits both type-1 and type2 isoforms of the enzyme and is used to treat benign prostatic hyperplasia.
BP10162	E-4031
BP10162	E-4031 is a methanesulfonanilide class III antiarrhythmic agent that prolongs cardiac action potential duration by blocking ERG K+ channels (IC50 = 29 nM)
BP10886	EAI045
BP10886	EAI045, an allosteric inhibitor, targets towards drug-resistant EGFR mutants but avoids the wild-type receptor.
BP10833	EB-3D
BP10833	EB-3D is a potent and selective choline kinase alpha 1 (ChoKα1) inhibitor(IC50 : 1 μM).with anti-cancer activity.
BP10872	eCF506
BP10872	eCF506 is a potent and selective inhibitor of SRC (IC50 < 0.5 nM)
BP10782	EGFR/ErbB-2/ErbB-4 inhibitor-2
BP10782	EGFR/ErbB2 Inhibitor is a cell-permeable inhibitor of EGFR and c-ErbB2 (IC50s = 20 and 79 nM, respectively)
BP10690	EGFR-IN-1
BP10690	EGFR-IN-1 displays strong antiproliferative activity against the H1975 cells and the first line mutant HCC827 cells. Antitumor activity. EGFR-IN-1 is an orally active and irreversible L858R/T790M mutant selective EGFR inhibitor. EGFR-IN-1 potently inhibits Gefitinib-resistant EGFR L858R, T790M with 100-fold selectivity over wild-type EGFR.
BP10379	EGFR-IN-16
BP10379	AG473 is an inhibitor of EGFR in human A431 cells.
BP10710	EGFR-IN-2
BP10710	EGFR-IN-2 is a non-covalent, mutation-selective and irreversible second-generation EGFR inhibitor.
BP10257	EGFR-IN-9
BP10257	EGFR-IN-9 has antitumor activity. EGFR-IN-9 is a potent EGFR kinase inhibitor with IC50s of 7 nM, 28 nM for the wild type EGFR kinase and double mutant EGFR kinase (L858R/T790M).